Synthetic method of robecoxib

By adopting hydrolysis and substitution reactions under alkaline conditions in the robecoxib synthesis, high-temperature reduction and metal catalysis of hydrazine hydrate are avoided, and high cost and safety risks under harsh conditions in the prior art are solved, thus achieving high efficiency, Low-cost robecoxib synthesis, suitable for industrial production.

CN119080627APending Publication Date: 2024-12-06WISDOM PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411461159.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-18
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing robocoxic synthesis method has harsh conditions such as metal catalytic reaction, hydrazine hydrate reduction and high temperature ring-closure, resulting in high cost, high safety risks and a lot of waste.

Method used

5-ethylindole-2-one was hydrolyzed under alkaline conditions, followed by reaction with chloroacetyl chloride, and substituted with 2,3,5,6-tetrafluorophenol in the presence of alkaline, through rearrangement The reaction produces robecoxib, avoiding high-temperature reduction of hydrazine hydrate and metal catalysis.

Benefits of technology

It realizes a mild reaction without high temperature, high pressure or ultra-low temperature conditions, reduces costs, reduces impurities, improves product purity and yield, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005091904460000011
    Figure BDA0005091904460000011
  • Figure BDA0005091904460000012
    Figure BDA0005091904460000012
  • Figure BDA0005091904460000021
    Figure BDA0005091904460000021
Patent Text Reader

Abstract

The invention discloses a method for synthesizing robecoxib from 5-ethyl indole-2-ketone, which is characterized in that the 5-ethyl indole-2-ketone and 2, 3, 5, 6-tetrafluorophenol are used as raw materials, and the robecoxib is prepared through hydrolysis, acylation, condensation and rearrangement reaction. Metal catalysis and hydrazine hydrate high-temperature reduction are avoided, the method is mild in condition and easy to operate, and the obtained product is high in yield and purity and especially suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to a method for synthesizing Robenacoxib, and belongs to the technical field of preparation of pharmaceutical compounds. Background Art

[0002] Robenacoxib is a non-steroidal anti-inflammatory analgesic drug and a selective COX-2 inhibitor. It is mainly used to treat inflammation, pain and fever in cats and dogs. It has a rapid onset of action in the blood-brain barrier of cats and dogs and is safer. It has fewer gastrointestinal adverse reactions and a lower risk of gastrointestinal ulcers and bleeding. In addition, Robenacoxib also has good efficacy and tolerability for single migraine attacks. Its chemical structure is as follows:

[0003]

[0004] At present, the synthesis methods of Robenacoxib mainly include the following:

[0005] The synthesis methods reported in Chinese patents CN1140500C and CN1268112A are similar, and are achieved by metal-catalyzed coupling reactions. The coupling reactions require harsh conditions such as anhydrous and oxygen-free conditions, and will produce heavy metal residues. The raw materials used are also relatively expensive. The synthesis route is as follows:

[0006]

[0007] The method disclosed in patent CN111807978B is: 2-indolone is subjected to Friedel-Crafts acylation, reduction reaction, Ullmann coupling, and hydrolysis to prepare Robenacoxib. This route also involves a copper-catalyzed coupling reaction, and the raw material tetrafluoroiodobenzene is expensive and difficult to obtain. Its synthetic route is as follows:

[0008]

[0009] Patent CN102311355A uses p-ethylaniline as the starting material, and obtains compound A through amidation, alkylation, and rearrangement reaction. Compound A is then condensed with chloroacetyl chloride, and subjected to Friedel-Crafts alkylation ring closure, and finally hydrolyzed to obtain Robenacoxib. This method does not require metal catalysis, but the Friedel-Crafts alkylation ring closure step requires high temperature conditions (140-180°C), high requirements for reaction equipment, and more impurities are generated. The specific reaction route is as follows:

[0010]

[0011] Similarly, CN109694330A starts with compound A, replaces chloroacetyl chloride with oxalyl chloride, and after amidation reaction, performs Friedel-Crafts acylation to form a ring, and then hydrolyzes and reduces with hydrazine hydrate at high temperature to obtain Robenacoxib. The overall steps are relatively long, and the high-temperature reduction with hydrazine hydrate has certain safety issues. The synthetic route is as follows:

[0012]

[0013] Patent CN115433117A records a method in which compound A reacts with trichloroacetaldehyde and hydroxylamine to generate an aldoxime intermediate B, which is then ring-closed and hydrolyzed in 90-98% sulfuric acid or polyphosphoric acid, and finally reduced with hydrazine hydrate at high temperature to obtain Robenacoxib. This method uses a large amount of sulfuric acid or polyphosphoric acid as a solvent, and adding water after post-treatment will produce a large amount of acidic wastewater, which is not friendly to the environment. It also involves a hydrazine hydrate high-temperature reduction step. The synthesis route is as follows:

[0014]

[0015] It can be seen that the existing methods for synthesizing Robenacoxib mainly involve metal-catalyzed coupling reactions, hydrazine hydrate reduction, high-temperature ring closure, etc., which have the problems of high cost, high safety risk and large amount of waste. Summary of the invention

[0016] The purpose of the present invention is to provide a new method for efficiently synthesizing Robenacoxib, which avoids harsh reaction conditions such as metal catalysis, hydrazine hydrate reduction, and high-temperature ring closure, and is suitable for industrial production.

[0017] The preparation method of Robenacoxib provided by the present invention comprises the following steps:

[0018] 1. The compound 5-ethylindole-2-one (Formula I) is hydrolyzed in a mixed solution of a first solvent and water under alkaline conditions to obtain a solution of the compound of Formula II;

[0019] 2. The solution of compound of formula II is concentrated, replaced with a second solvent, and then reacted with chloroacetyl chloride to obtain compound of formula III;

[0020] 3. Compound III undergoes substitution reaction with 2,3,5,6-tetrafluorophenol in the presence of a first base to obtain compound IV. Compound IV undergoes rearrangement reaction in the presence of a second base to produce Robenacoxib. The reaction scheme is as follows:

[0021]

[0022] in,

[0023] In step 1 above,

[0024] Using 5-ethylindole-2-one (Formula I) as a raw material, hydrolyzing it in a mixed solution of a first organic solvent and water under alkaline conditions, desolventizing and drying under reduced pressure to obtain a compound of Formula II, wherein the hydrolysis temperature is 40-80° C., preferably 60-80° C.;

[0025] The first solvent is any one of methanol, ethanol and isopropanol, preferably ethanol;

[0026] The base is any one of sodium hydroxide, potassium hydroxide and lithium hydroxide, preferably lithium hydroxide; the molar ratio of the base to formula I is 2.0 to 4.0:1, preferably 3.0:1.

[0027] In step 2 above,

[0028] The compound II obtained in step 1 is added to the second solvent, reacted with chloroacetyl chloride, and then post-treated with hydrochloric acid to obtain the compound III.

[0029] The reaction temperature is 10-80°C, preferably 20-30°C;

[0030] The molar ratio of chloroacetyl chloride to formula I is 1.2 to 2.0:1, preferably 1.5:1;

[0031] The second solvent is any one of tetrahydrofuran, N,N-dimethylformamide, and dimethyl sulfoxide, preferably tetrahydrofuran. In the above step 3,

[0032] Using compound III as a raw material, in an organic solvent, in the presence of a first base, and tetrafluorophenol, a substitution reaction is carried out to obtain compound IV, and then a rearrangement reaction is carried out under a second base condition to obtain the carboxylate of Robenacoxib, and then post-treatment is carried out by acidification with hydrochloric acid, separation and purification to obtain Robenacoxib;

[0033] The first base is any one of potassium carbonate, sodium carbonate and cesium carbonate, preferably potassium carbonate;

[0034] The molar ratio of the first base to formula III is 1.5 to 3.0:1, preferably 2.0:1;

[0035] The reaction temperature of the substitution reaction is 30-80°C, preferably 70-80°C;

[0036] The second alkali is any one of sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium ethoxide, sodium methoxide, etc., preferably potassium hydroxide;

[0037] The molar ratio of the second base to formula IV is 2.0 to 4.0:1, preferably 2.0:1;

[0038] The rearrangement reaction temperature is 30-80°C, preferably 50-60°C;

[0039] The organic solvent is any one of ethanol and isopropanol, preferably isopropanol.

[0040] The technical solution of the present invention has achieved the following beneficial effects:

[0041] (1) The process does not involve high-temperature reduction of hydrazine hydrate, thus avoiding the implementation of dangerous reactions.

[0042] (2) The process does not involve metal catalysis, which reduces costs, avoids heavy metal residues in the product, and improves the quality of the API.

[0043] (3) The process does not involve high-temperature cyclization reaction, which reduces the generation of impurities.

[0044] (4) The reaction conditions are mild, the operation is simple and easy to control; there are no reactions requiring harsh conditions such as high temperature, high pressure or ultra-low temperature.

[0045] (5) The technical solution of the present application has a short process step, and the intermediates of Formula II and Formula IV do not need to be separated and purified. Only one intermediate (Formula III) needs to be separated and purified, which generates less waste, and the total yield and purity of the obtained product are high, which is suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Attached Figure 1 This is a single crystal spectrum of Robenacoxib prepared in the present invention.

[0047] Attached Figure 2 The figure is the nuclear magnetic hydrogen spectrum of Robenacoxib prepared by the present invention.

[0048] Attached Figure 3 The HPLC chart of Robenacoxib prepared in the present invention is shown in FIG. DETAILED DESCRIPTION

[0049] In order to enable those skilled in the art to better understand the technical solution of the present invention, some non-limiting embodiments are further disclosed below to further describe the present invention in detail.

[0050] Example 1

[0051] (1) Preparation of compound III

[0052] 5-Ethylindol-2-one (Formula I) (6.0 g, 37.2 mmol), ethanol (30.0 ml), water (3.0 ml), lithium hydroxide monohydrate (4.7 g, 112.0 mmol) were added to the reaction flask, reacted at 80°C for 36 hours, and distilled under reduced pressure at 50°C to obtain compound II. Tetrahydrofuran (25.0 ml) and chloroacetyl chloride (6.3 g, 55.8 mmol) were directly added, and the mixture was kept at 20-30°C for 6 hours. Water (40.0 ml) and methyl tert-butyl ether (40.0 ml) were added and stirred for 0.5 hour. The organic phase was separated, and the aqueous phase was adjusted to pH 2.0 with concentrated hydrochloric acid, stirred for 0.5 hour, filtered, and dried to obtain 8.1 g of an off-white solid, with a yield of 85.1%. 1H-NMR (400MHz, DMSO-d6): δ12.34(br,1H),9.72(s,1H),7.30(d,J=8.7Hz,1H),7. 11(m,2H),4.27(s,2H),3.57(s,2H),2.57(q,J=7.5Hz,2H),1.17(t,J=7.6Hz,3H).

[0053] (2) Preparation of Robenacoxib

[0054] Compound III (5.0 g, 19.6 mmol), isopropanol (50.0 ml), potassium carbonate (5.4 g, 39.2 mmol), 2,3,5,6-tetrafluorophenol (3.3 g, 19.6 mmol) were added to the reaction flask, reacted at 70°C for 6 hours, cooled to 50°C, added sodium hydroxide (1.6 g, 39.2 mmol) and reacted for 24 hours, the reaction solution was dried under reduced pressure, water (50.0 ml) and methyl tert-butyl ether (50.0 ml) were added, the organic phase was separated after stirring, the aqueous phase was adjusted to pH 2.0 with concentrated hydrochloric acid, methyl tert-butyl ether (50 ml) was added for extraction, the aqueous phase was separated, dried under reduced pressure at 50°C, toluene (50 ml) was added, the temperature was raised to 80°C, the temperature was lowered to 20°C, stirred for 2 hours, and filtered. 5.7 g of white solid was obtained after drying, purity: 99.67%, yield: 89.1%. 1 H-NMR (400MHz, DMSO-d6): δ12.50(br,1H),7.63(s,1H),7.31(m,1H),7.07(m,1H),7 .01(m,1H),6.80(m,1H),3.67(s,2H),2.53(d,J=7.6Hz,2H),1.16(t,J=7.6Hz,3H).

[0055] Example 2

[0056] (1) Preparation of compound III

[0057] Add 5-ethylindole-2-one (Formula I) (6.0 g, 37.2 mmol), methanol (30.0 ml), water (3.0 ml), potassium hydroxide (6.3 g, 112.0 mmol) to the reaction flask, react at 65°C for 48 hours, and distill under reduced pressure at 50°C to obtain compound II, directly add dimethylformamide (25.0 ml) and chloroacetyl chloride (6.3 g, 55.8 mmol), keep warm at 20-30°C for 6 hours, add water (40.0 ml) and methyl tert-butyl ether (40.0 ml) and stir for 0.5 hour, separate the organic phase, adjust the pH of the aqueous phase to 2.0 with concentrated hydrochloric acid, stir for 0.5 hour, filter, and dry to obtain 8.1 g of off-white solid, yield: 82.1%;

[0058] (2) Preparation of Robenacoxib

[0059] Compound III (5.0 g, 19.6 mmol), ethanol (50.0 ml), sodium carbonate (4.2 g, 39.2 mmol), 2,3,5,6-tetrafluorophenol (3.3 g, 19.6 mmol) were added to the reaction flask, reacted at 80°C for 6 hours, cooled to 60°C, added sodium ethoxide (2.9 g, 39.2 mmol) and reacted for 24 hours, the reaction solution was dried under reduced pressure at 50°C, water (50.0 ml) and methyl tert-butyl ether (50.0 ml) were added, the organic phase was separated after stirring, the aqueous phase was adjusted to pH 2.0 with concentrated hydrochloric acid, methyl tert-butyl ether (50 ml) was added for extraction, the aqueous phase was separated, dried under reduced pressure at 50°C, toluene (50 ml) was added, the temperature was raised to 80°C, the temperature was lowered to 20°C, stirred for 2 hours, and filtered. 5.6 g of white solid was obtained after drying, with a yield of 87.5%.

[0060] The embodiments of the present invention are described in detail above, but the contents described are only preferred embodiments of the present invention and cannot be considered to limit the scope of implementation of the present invention. All equivalent changes and improvements made within the scope of the present invention should still fall within the scope of the patent coverage of the present invention.

Claims

1. A method for synthesizing Robenacoxib from 5-ethylindol-2-one, comprising the following steps: (1) The compound 5-ethylindole-2-one (Formula I) is hydrolyzed under alkaline conditions in a mixed solution of a first solvent and water, and desolventized under reduced pressure to obtain a compound of Formula II; (2) Compound II is added to a second solvent, reacted with chloroacetyl chloride, and then acidified with hydrochloric acid to obtain compound III; (3) Compound III and 2,3,5,6-tetrafluorophenol undergo a substitution reaction in an organic solvent in the presence of a first base to obtain compound IV, which undergoes a rearrangement reaction in the presence of a second base, is post-treated with hydrochloric acid, and separated and purified to obtain Robenacoxib; the reaction route is as follows: Note: The compounds in brackets have not been isolated and purified in, M is a potassium ion, a sodium ion, or a lithium ion.

2. The method of claim 1, wherein in the reaction for preparing compound of formula II, the first solvent is any one of methanol, ethanol, and isopropanol, preferably ethanol.

3. The method of claim 1, wherein in the reaction for preparing compound of formula II, the base is any one of sodium hydroxide, potassium hydroxide, and lithium hydroxide, preferably lithium hydroxide, and the molar ratio of the base to formula I is 2.0 to 4.0:1, preferably 3.0:

1.

4. The method of claim 1, wherein in the reaction for preparing the compound of formula III, the second solvent is any one of tetrahydrofuran, N,N-dimethylformamide, and dimethyl sulfoxide, preferably tetrahydrofuran.

5. The method of claim 1, wherein in the reaction for preparing the compound of formula III, the molar ratio of chloroacetyl chloride to formula I is 1.2 to 2.0:1, preferably 1.5:

1.

6. The method of claim 1, wherein in the reaction for preparing the compound of formula IV, the first base is any one of potassium carbonate, sodium carbonate, and cesium carbonate, preferably potassium carbonate, and the molar ratio of the base to formula III is 1.5 to 3.0:1, preferably 2.0:

1.

7. The method of claim 1, wherein in the reaction for preparing Robenacoxib, the second base is any one of sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium ethoxide, sodium methoxide, etc., preferably potassium hydroxide; and the molar ratio of the base to formula III is 1.0 to 3.0:1, preferably 2.0:

1.

8. The method according to claim 1, wherein in the reaction for preparing Robenacoxib, the organic solvent is any one of ethanol and isopropanol, preferably isopropanol.